Cybin Inc. (NEO: CYBN) At the Forefront of Psychedelic Therapeutic Protocols, Development

Big pharma and life science companies are making big news these days. The drug-development space is seeing strong investor interest as these companies make breakthrough advancements that address vast unmet medical needs. Strategic M&A moves are adding spice to the gumbo for investors as pioneering research remains focused on providing life-changing treatments for those suffering from a myriad of disorders. One of the largest and trickiest medical disorders of mankind may be on the cusp of more effective treatment. Depression is often kept in the dark and not talked about, but it is estimated that more than 17 million adults in the United States experienced at least one major depressive episode in 2019 alone, while one out of every four people in the world struggle with a diagnosable mental disorder. Life sciences company Cybin Inc. (Cybin Profile) is at the vanguard of new therapeutic protocols that target these disorders. Cybin is intent on developing psychedelic therapeutics along with unique delivery mechanisms that target depression as well as other psychiatric and neurological conditions. The company could benefit from two game-changing announcements made in the past few days: the company just completed its previously announced reverse takeover and a groundbreaking study published in JAMA Psychiatry reports that in a recent study a treatment featuring psilocybin actually worked better than typical antidepressant medications. Other drug-development companies are experiencing similar milestone moments. Last month Praxis Precision Medicines Inc. (NASDAQ: PRAX) closed on its upsized initial public offering of 11,500,000 shares of common stock, resulting in aggregate gross proceeds to Praxis of $218.5 million. Earlier this year, AbbVie Inc. (NYSE: ABBV) completed a transformative acquisition of Allergan. Less than a year ago, Axsome Therapeutics (NASDAQ: AXSM) realized more than $200 million when it closed on its public offering. And this summer Relmada Therapeutics Inc. (NASDAQ: RLMD) uplisted to trade on the Nasdaq Global Select Market.